Bristol-Myers Squibb에 대한 매도 수량은 투자자에게 Bristol-Myers Squibb의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Bristol-Myers Squibb (NYSE:BMY) 주식, 공매도 수량 보고

Bristol-Myers Squibb

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Earnings

Large Cap

Macro Economic Events

Mid Cap

Sector ETFs

Eurozone

Commodities

Small Cap

Econ #s

Economics

Federal Reserve

Markets

Tech

ETFs

GOOGL

TSLA

기술기업들 수익 시즌은 거래 주간 동안 매그니피센트 세븐 회사들의 주가가 모두 하락함에 따라 투자자들의 실망으로 시작되었다. 알파벳(NASDAQ:GOOGL)은 예상보다 높은 매출과 이익을 발표했지만, 유튜브 광고 매출에 대한 분석가들의 목표를 달성하지 못해 구글의 모회사 주가가 올해 최악의 한 주가 되었다.

이번 주 시장 동향: 기술주가 수익률 하락, 강력한 미국 경제로 소형주는 계속 상승세

News

Pre-Market Outlook

Trading Ideas

CHTR

DECK

금요일 아침 (현지 시간 기준) 미국 주식 선물이 더 높게 거래되면서 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다: 월스트리트는 브리스톨-마이어스 스퀴브(NYSE:BMY)가 개장 전 115억 5천만 달러의 매출과 주당 1.63달러의 분기 이익을 보고할 것으로 예상하고 있다. Benzinga Pro의 데이터에 따르면, 브리스톨-마이어스 스퀴브의 주가는 시간외 거래에서 0.4% 하락한 45.10달러를 기록했다.

금요일 주목해야 할 주식: 브리스톨-마이어스 스퀴브, 데커스 아웃도어 그리고 3종목

Equities

Previews

ABBV

AGYS

ASML

BJRI

CHKP

CMCSA

GATX

GOOG

JNPR

NFLX

NXPI

ODFL

ORLY

SKYW

SPOT

VRSN

S&amp;P 500 기업들 중 약 14%가 6월 분기 실적을 발표했으며, 더 넓은 지수를 구성하는 기업들의 혼합 실적 성장률은 여전히 ​​양호하다. 이번 주에는 기술 보고 시즌이 공식적으로 시작될 것이며, 이는 최근 주에 가파른 하락세를 보인 시장의 향방을 잠재적으로 결정할 수 있다.

테슬라, 알파벳, GM 및 포드가 이번 주 실적 발표 주도하며 상승세 유지 위해 고군분투

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb Co

BRISTOL-MYERS SQUIBB $2PR by Bristol-Myers Squibb Co.

According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping investor outlook for 2025.
Despite strong fundamentals and advancements in drug pipelines, factors such as political uncertainty and sector rotation have hindered the sector's performance relative to the S&amp;P 500.
In 2024, biopharma stocks rose by 9.6%, falling short of the S&amp;P 500's 28.5% surge. However, JP Morgan analysts maintain a positive outlook for several key players.
Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), a top pick for the firm, is projected to see continued growth in its diabetes and obesity treatments, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua" rel="noreferrer noopener">Mounjaro and Zepbound</a>. The analyst also pointed to the company's robust pipeline and forecasted double-digit revenue and earnings growth into the 2030s.
Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) has been added to JP Morgan's Analyst Focus List due to the strong potential of its schizophrenia drug, Cobenfy, which could achieve peak sales of $10 billion.
Similarly, Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) are expected to recover in 2025, following challenges in 2024 related to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38208816/eye-drug-eylea-price-manipulation-regeneron-faces-us-justice-department-allegations-over-medicare" rel="noreferrer noopener">competitive pressures </a>and regional dynamics <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168774/mercks-blockbuster-vaccine-gardasil-sales-in-china-analyst-highlights-challenges-an" rel="noreferrer noopener">affecting key products</a>.
Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is poised for growth with the anticipated mid-2025 launch of lenacapavir <a target="_blank" href="https://www.benzinga.com/quote/GILD" rel="noreferrer noopener">for HIV prevention</a>.
The firm also highlighted AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) for its appealing valuation, supported by strong Skyrizi and Rinvoq sales despite fewer near-term <a target="_blank" href="https://www.benzinga.com/quote/ABBV" rel="noreferrer noopener">pipeline developments</a>.
Animal health stocks are also projected to rebound in 2025. JP Morgan views Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) as the strongest pick in the sector, citing its potential for high single-digit revenue <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722660/zoetis-q3-earnings-beat-companion-animal-segment-growth-gives-confidence-into-2025-" rel="noreferrer noopener">growth and margin expansion</a>. IDEXX Laboratories, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) is another solid choice, though its performance depends on a r<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41659873/idexx-laboratories-adjusts-guidance-as-q3-revenue-growth-slows-analyst-notes-fewer-" rel="noreferrer noopener">ecovery in veterinary visits</a>. Meanwhile, Elanco Animal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) faces uncertainties linked to its <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" rel="noreferrer noopener">new product launches</a>.
Specialty pharmaceuticals showed early signs of stabilization in 2024, benefiting from improved pricing stability and supply dynamics. Perrigo Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) and Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) are highlighted as promising opportunities, while Teva Pharmaceuticals Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) may face growth challenges despite delivering strong clinical trial <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" rel="noreferrer noopener">results this year</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42623487/jp-morgan-defensive-oil-stocks-to-watch-in-2025-amid-70-brent-forecast" target="_blank" rel="noreferrer noopener">Defensive Oil Stocks To Watch In 2025 Amid $70 Brent Forecast: JP Morgan</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Biotech

Health Care

Analyst Ratings

General

ELAN

GILD

IDXX

PRGO

REGN

TEVA

VTRS

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More

According to a report, U.S. healthcare spending grew by 7.5% to $4.9 trillion in 2023. The increase was fueled by higher enrollment in private health plans and expanded use of medical services, driven by legislative changes and post-pandemic rebounds in care utilization.
Healthcare spending accounted for 17.6% of the U.S. economy, outpacing GDP growth of 2.9%. Spending on retail prescription drugs <a target="_blank" href="https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2024.01375" rel="noreferrer noopener">saw</a> the most significant rise, jumping 11.4% to $449.7 billion.
The report attributed this to increased use of medications for obesity and diabetes.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
The rapid growth in spending for drugs used to treat diabetes and obesity contributed to faster overall growth in retail prescription drug expenditures and private health insurance and Medicare spending growth.
Hospital care spending rose 10.4% to $1.5 trillion in 2023, marking the fastest growth since 1990. Hospital discharges increased by 1.6%, with Medicare beneficiaries driving higher outpatient service utilization.
Spending on physician and clinical services also climbed by 7.4% to $978 billion, with private insurance and Medicare patients contributing to this rise.
Enrollment in private health insurance grew by 1.6%, adding 3.3 million Americans.
Private insurance spending surged by 11.5%, reaching $1.5 trillion and accounting for 30% of national healthcare expenditures.
Medicare spending grew 8.1% to $1 trillion, representing 21% of total healthcare spending. Medicaid spending, however, grew more slowly at 7.9%, reflecting the end of the COVID-19 public health emergency.
The report also revealed that 92.5% of Americans had health insurance in 2023, up from 92.0% in 2022, underscoring the broader coverage expansion in recent years.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/24/12/42599673/amazon-has-20000-rivian-electric-delivery-vans-in-fleet-heres-what-could-be-next-for-both-companies">Amazon Has 20,000 Rivian Electric Delivery Vans In Fleet: Here&#8217;s What Could Be Next For Both Companies</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Government

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

iShares Dow Jones US Pharmaceuticals Index Fund

iShares Dow Jones US Health Care Provides Index Fund

iShares Trust Dow Jones US Healthcare Sector Index Fund

Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) for BioArctic's PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program, including BAN1503 and BAN2803, whereof the latter includes BioArctic's BrainTransporter&#x2122;&nbsp;technology.&nbsp;As part of the agreement, BioArctic will receive a USD 100 million upfront payment and up to USD 1.25 billion in milestone payments. BioArctic is also entitled to tiered low double-digit royalties on global product sales.

BRCTF

BioArctic Partners With Bristol Myers Squibb In Licensing Deal For PyroGlutamate-Amyloid-Beta Antibody Program

insitro Receives $25M In Milestone Payments From Bristol Myers Squibb For Achievement Of Discovery Milestones And Selection Of First Novel Genetic Target For ALS

The Health Resources and Services Administration (HRSA) has warned Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) about its proposed credit model for certain outpatient drugs under the 340B program.
HRSA asserts that the credit system, beginning on January 6, 2025, violates Sanofi's legal obligations under the 340B statute.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/42097386/cvs-healthcignaunitedhealths-pharmacy-benefit-managers-accuse-ftc-of-overreach-in-effort-to-reshape-drug-rebate-system" rel="noreferrer noopener">Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System</a>
Sanofi <a target="_blank" href="https://www.hrsa.gov/sites/default/files/hrsa/opa/dec-13-2024-hrsa-letter-sanofi.pdf" rel="noreferrer noopener">announced</a> in a November 22, 2024, notice that it would introduce a credit model for covered outpatient drugs for specific covered entities, including disproportionate share hospitals, critical access hospitals, rural referral centers, and sole community hospitals.
Under this plan, these entities would pay the Wholesale Acquisition Cost (WAC) upfront and later submit purchase and claim data to receive a credit representing the 340B price difference. Starting March 1, 2025, this model would include consolidated health centers.
Additionally, Sanofi's notice requires hospitals to submit healthcare encounter data to verify claims based on HRSA's 1996 patient guidelines, effective March 1, 2025.
The criteria include ensuring the individual receiving the drug is under the covered entity's care and that prescriptions are tied to services provided by the entity.
HRSA emphasized that the 340B statute establishes a ceiling price as the maximum amount covered entities can be charged for outpatient drugs. Any manufacturer must offer drugs at or below this ceiling price without imposing additional conditions. Sanofi's proposed credit model, which mandates payment above this price without prior approval, directly contradicts the statute.
The agency also warned that proceeding with the credit proposal could lead to severe consequences for Sanofi. These include potential termination of its Pharmaceutical Pricing Agreement (PPA) and civil monetary penalties.
The 340B statute allows sanctions for manufacturers that knowingly overcharge covered entities.
HRSA has instructed Sanofi to halt the implementation of this credit model immediately and provide confirmation by December 20, 2024.
Bristol-Myers Squibb Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) filed a lawsuit against HRSA and the U.S. Department of Health and Human Services, alleging that HRSA's rejection of its proposed rebate model for the 340B Drug Pricing Program <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42248288/bristol-myers-squibb-files-lawsuit-against-us-agency-for-overreach-in-340b-drug-pricing-program" rel="noreferrer noopener">violates federal law</a>.
Price Action: At last check Tuesday, SNY stock was up 4.14% at $47.79 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42514598/hubspots-ai-powered-tools-set-to-drive-smb-growth-and-crm-innovation-analyst-says" target="_blank" rel="noreferrer noopener">HubSpot To Dominate SMB CRM Space With AI-Driven Platform, Says BofA Analyst</a></li>
</ul>
Image by HJBC via Shutterstock

Sanofi's 340B Credit Proposal Draws Federal Warning For Statutory Violation

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul>
<li>Dividend Yield: 5.71%</li>
<li>Truist Securities analyst David Macdonald reiterated a Buy rating and cut the price target from $76 to $67 on Nov. 20. This analyst has an accuracy rate of 66%.</li>
<li>UBS analyst Kevin Caliendo maintained a Neutral rating and raised the price target from $60 to $62 on Nov. 7. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: On Monday, CVS Health announced early results of maximum tender offer and election of early settlement.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121724&amp;t=be2bearmibe3na1">latest CVS new</a>s. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="836" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034652/image-141.png" alt="" class="wp-image-695397" style="width:589px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034652/image-141.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034652/image-141-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034652/image-141-768x712.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 4.44%</li>
<li>B of A Securities analyst Tim Anderson reinstated a Neutral rating with a price target of $63 on Dec. 10. This analyst has an accuracy rate of 61%.</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and raised the price target from $55 to $60 on Nov. 12. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: On Dec. 13, Bristol Myers Squibb said its Board of Directors declared a quarterly dividend of 62 cents per share on the $0.10 par value common stock of the company.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121724&amp;t=be2bearmibe3na1">latest BMY news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034734/image-142.png" alt="" class="wp-image-695399" style="width:634px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034734/image-142.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034734/image-142-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034734/image-142-768x705.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</h3>
<ul>
<li>Dividend Yield: 3.82%</li>
<li>B of A Securities analyst Tim Anderson reinstated a Neutral rating with a price target of $191 on Dec. 10. This analyst has an accuracy rate of 61%.</li>
<li>Leerink Partners analyst David Risinger upgraded the stock from Market Perform to Outperform with a price target of $206 on Nov. 22. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: On Dec. 13, AbbVie announced plans to acquire Nimble Therapeutics.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121724&amp;t=be2bearmibe3na1">trend in ABBV stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="915" height="851" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034808/image-143.png" alt="" class="wp-image-695400" style="width:570px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034808/image-143.png 915w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034808/image-143-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034808/image-143-768x714.png 768w" sizes="(max-width: 915px) 100vw, 915px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42507875/how-to-earn-500-a-month-from-worthington-enterprises-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Worthington Enterprises Stock Ahead Of Q2 Earnings</a></li>
</ul>

Dividends

Price Target

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

Bristol-Myers Squibb Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) shares saw are trading higher Monday. Jefferies analyst, Akash Tewari, raised his rating on the stock from Hold to Buy and increased the price target from $63 to $70. Here&#8217;s<a href="https://www.benzinga.com/quote/BMY/news"> what you need to know</a>.
What To Know: The analyst's upgrade comes after increased confidence in several aspects of Bristol-Myers Squibb's business, particularly its pipeline and upcoming product launches. Tewari highlighted three key reasons for the upgrade.
Tewari believes Cobenfy (KarXT), a treatment for schizophrenia and bipolar disorder, is on track to become a $10 billion-plus drug. He is bullish on the drug&#8217;s launch in schizophrenia, as well as its potential in treating Alzheimer&#8217;s psychosis and bipolar disorder. He expects strong sales growth in the coming years, with a 2025 forecast of $215 million, significantly above consensus estimates.
The analyst expressed confidence that Milvexian, a drug in development for atrial fibrillation, could achieve positive results in non-inferiority trials, further supporting the company&#8217;s growth prospects. He also noted improved visibility on Bristol-Myers Squibb's financials, driven by positive momentum from recent product launches and growing clarity on cost control measures. As a result, he raised his earnings-per-share projections, expecting the company to reach EPS floor of $6 in the near future.
Additionally, the company's ongoing collaboration with Immatics N.V. remains intact, despite the recent termination of other partnership agreements, including the allogeneic and opt-in collaborations with BMS. While this move reflects ongoing portfolio prioritization efforts, the termination does not require Bristol-Myers Squibb to refund any of the upfront payments.
With a new price target of $70, Jefferies sees upside potential in Bristol-Myers Squibb's stock.
BMY Price Action: Bristol-Myers Squibb shares were up 0.14% at $55.86 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="522" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16153356/er-1024x522.png" alt="" class="wp-image-694648" style="width:564px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16153356/er-1024x522.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16153356/er-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16153356/er-768x391.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16153356/er.png 1235w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/12/42516580/ionq-quantum-computing-and-rigetti-computing-shares-are-soaring-monday-whats-going-on">IonQ, Quantum Computing And Rigetti Computing Shares Are Soaring Monday: What&#8217;s Going On?</a></li>
</ul>
Image Via Shutterstock.

Movers

Bristol-Myers Squibb Shares Rise After Analyst Upgrades, Positive Pipeline Outlook

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$17.00</td>
<td>$167.5K</td>
<td>17.1K</td>
<td>2.9K</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$500.00</td>
<td>$29.9K</td>
<td>1.3K</td>
<td>2.2K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$50.00</td>
<td>$54.7K</td>
<td>6.6K</td>
<td>1.8K</td>
</tr>
<tr>
<td>CI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$180.00</td>
<td>$292.5K</td>
<td>6.2K</td>
<td>1.6K</td>
</tr>
<tr>
<td>VRDN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$22.50</td>
<td>$27.0K</td>
<td>458</td>
<td>599</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$580.00</td>
<td>$57.1K</td>
<td>475</td>
<td>250</td>
</tr>
<tr>
<td>PRAX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$80.00</td>
<td>$45.0K</td>
<td>14</td>
<td>99</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$40.00</td>
<td>$32.6K</td>
<td>615</td>
<td>25</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$25.00</td>
<td>$25.1K</td>
<td>42</td>
<td>12</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we observe a call option trade with bullish sentiment. It expires in 4 day(s) on December 20, 2024. Parties traded 2500 contract(s) at a $17.00 strike. The total cost received by the writing party (or parties) was $167.5K, with a price of $67.0 per contract. There were 17104 open contracts at this strike prior to today, and today 2970 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option trade that happens to be neutral, expiring in 4 day(s) on December 20, 2024. This event was a transfer of 38 contract(s) at a $500.00 strike. The total cost received by the writing party (or parties) was $29.9K, with a price of $788.0 per contract. There were 1381 open contracts at this strike prior to today, and today 2262 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option sweep that happens to be bearish, expiring in 4 day(s) on December 20, 2024. This event was a transfer of 205 contract(s) at a $50.00 strike. This particular put needed to be split into 25 different trades to become filled. The total cost received by the writing party (or parties) was $54.7K, with a price of $267.0 per contract. There were 6605 open contracts at this strike prior to today, and today 1828 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a call option trade that happens to be bearish, expiring in 760 day(s) on January 15, 2027. This event was a transfer of 25 contract(s) at a $180.00 strike. The total cost received by the writing party (or parties) was $292.5K, with a price of $11700.0 per contract. There were 6297 open contracts at this strike prior to today, and today 1688 contract(s) were bought and sold. 
• For VRDN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>), we notice a call option trade that happens to be bearish, expiring in 4 day(s) on December 20, 2024. This event was a transfer of 200 contract(s) at a $22.50 strike. The total cost received by the writing party (or parties) was $27.0K, with a price of $135.0 per contract. There were 458 open contracts at this strike prior to today, and today 599 contract(s) were bought and sold. 
• Regarding MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we observe a put option sweep with bearish sentiment. It expires in 4 day(s) on December 20, 2024. Parties traded 56 contract(s) at a $580.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $57.1K, with a price of $1020.0 per contract. There were 475 open contracts at this strike prior to today, and today 250 contract(s) were bought and sold. 
• Regarding PRAX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>), we observe a call option trade with bullish sentiment. It expires in 32 day(s) on January 17, 2025. Parties traded 98 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $45.0K, with a price of $460.0 per contract. There were 14 open contracts at this strike prior to today, and today 99 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a call option trade with neutral sentiment. It expires in 95 day(s) on March 21, 2025. Parties traded 20 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $32.6K, with a price of $1630.0 per contract. There were 615 open contracts at this strike prior to today, and today 25 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option trade that happens to be neutral, expiring in 151 day(s) on May 16, 2025. This event was a transfer of 10 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $25.1K, with a price of $2517.0 per contract. There were 42 open contracts at this strike prior to today, and today 12 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

PRAX

VKTX

VRDN

9 Health Care Stocks With Whale Alerts In Today's Session

On December 12, 2024, Bristol Myers Squibb (&quot;BMS&quot;) notified Immatics N.V. (the &quot;Company&quot;) that, due to ongoing portfolio prioritization efforts within BMS, it has elected to terminate the collaboration agreement, dated June 1, 2022, between Celgene Switzerland LLC and Immatics US, Inc., relating to the development of allogeneic programs, and the opt-in agreement, dated April 28, 2023, between Celgene Switzerland LLC and Immatics GmbH, relating to a target under the parties&#39; multi-target TCR-T strategic collaboration. The terminations are effective as of March 12, 2025. The Company is not obligated to refund BMS any part of the $60 million upfront payment received under the collaboration agreement or the $15 million opt-in payment received under the opt-in agreement. The Company&#39;s collaboration with BMS under the 2019 multi-target TCR-T strategic collaboration agreement remains ongoing.

Contracts

IMTX

Reported Friday, December 13, 2024, Bristol Myers Squibb Terminates Agreements with Immatics Due To Ongoing Portfolio Prioritization Efforts Within BMS For Allogeneic Programs; Collaboration With BMS Under The 2019 Multi-Target TCR-T Strategic Collaboration Agreement Remains Ongoing

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Stifel raised the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from $490 to $494. Stifel analyst Paul Matteis maintained a Hold rating. Vertex Pharmaceuticals shares closed at $463.73 on Friday. See how other analysts view this stock.</li>
<li>Jefferies raised the price target for Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) from $63 to $70. Jefferies analyst Akash Tewari upgraded the stock from Hold to Buy. Bristol-Myers Squibb shares closed at $55.78 on Friday. <a href="https://www.benzinga.com/quote/BMY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Oppenheimer boosted the price target for Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) from $825 to $1,065. Oppenheimer analyst Jason Helfstein maintained an Outperform rating. Netflix shares closed at $918.87 on Friday. <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley cut MKS Instruments, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) price target from $155 to $150. Morgan Stanley analyst Joseph Moore maintained an Overweight rating. MKS Instruments shares settled at $112.55 on Friday. <a href="https://www.benzinga.com/quote/MKSI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital raised RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) price target from $320 to $450. Loop Capital analyst Anthony Chukumba maintained a Hold rating. Walmart shares closed at $446.04 on Friday. <a href="https://www.benzinga.com/quote/RH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank cut NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) price target from $92 to $82. Deutsche Bank analyst Krisztina Katai maintained a Buy rating. NIKE shares closed at $77.25 on Friday.  <a href="https://www.benzinga.com/quote/NKE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt raised The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) price target from $122 to $135. Rosenblatt analyst Barton Crockett maintained a Buy rating. Disney shares closed at $113.34 on Friday. See how other analysts view this stock.</li>
<li>Mizuho cut the price target for Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) from $137 to $134. Mizuho analyst Nitin Kumar maintained a Neutral rating. Exxon Mobil shares settled at $110.84 on Friday. <a href="https://www.benzinga.com/quote/XOM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho raised CNX Resources Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNX#NYSE">CNX</a>) price target from $33 to $38. Mizuho analyst Nitin Kumar downgraded the stock from Neutral to Underperform. CNX Resources shares closed at $37.79 on Friday. <a href="https://www.benzinga.com/quote/CNX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush raised Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) price target from $400 to $515. Wedbush analyst Daniel Ives maintained an Outperform rating. Tesla shares closed at $436.23 on Friday. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying TSLA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="483" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126-1024x483.png" alt="" class="wp-image-693891" style="width:557px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126-1024x483.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126-300x142.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126-768x362.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126.png 1176w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42482639/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-with-over-6-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks With Over 6% Dividend Yields</a></li>
</ul>

MKSI

VRTX

Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday

Jefferies analyst Akash Tewari upgrades Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) from Hold to Buy and raises the price target from $63 to $70.

Upgrades

Jefferies Upgrades Bristol-Myers Squibb to Buy, Raises Price Target to $70

<figure class="table"> 
<table>
<tbody>
<tr>
<td> Termination of a Material Definitive Agreement</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;
On January 7, 2022, Century Therapeutics, Inc. (the "Company") entered into a Research, Collaboration and License Agreement (the "Collaboration Agreement") with Bristol-Myers Squibb Company ("BMS") to collaborate on the research, development and commercialization of induced pluripotent stem cell derived, engineered natural killer cell and/or gamma delta T cell programs for hematologic malignancies.
&nbsp;
Following an internal corporate portfolio prioritization process, BMS notified the Company on December 12, 2024 that it would be terminating the Collaboration Agreement in its entirety without cause. The termination will be effective on March 12, 2025. The Company is encouraged by the scientific progress on the programs and will evaluate opportunities in acute myeloid leukemia and multiple myeloma in the context of the ongoing strategic review of Century's pre-clinical pipeline. Both parties will work together in accordance with the termination provisions of the Collaboration Agreement.

IPSC

Bristol-Myers Squibb Notified Century Therapeutics On Dec 12 To Terminate Collaboration Agreement, Effective March 12, 2025; Co To Evaluate Opportunities In AML And Multiple Myeloma  In The Context Of The Ongoing Strategic Review Of Century's Pre-clinical Pipeline

Offerings

Bristol-Myers Squibb Co Files For Mixed Shelf; Size Not Disclosed

The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes.
Gilead Sciences Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) Biktarvy, Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Darzalex, Novartis AG's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Entresto, Exelixis Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) Cabometyx, and Pfizer Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Xeljanz are among the five drugs flagged for unsupported price increases.
These five drugs' unsupported net price increases <a target="_blank" href="https://icer.org/news-insights/press-releases/icer-announces-most-significant-drug-price-hikes-unsupported-by-new-clinical-evidence-in-us/" rel="noreferrer noopener">produced</a> $815 million in incremental added costs to U.S. payers in 2023. These price increases contributed significantly to the overall spending surge.
ICER's analysis <a target="_blank" href="https://icer.org/wp-content/uploads/2024/12/UPI_2024_Report_121224.pdf" rel="noreferrer noopener">revealed</a> that the other five drugs on the list did demonstrate new clinical evidence to justify their increased costs.
Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda, AstraZeneca Plc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Imfinizi and Tagrisso, Bristol Myers Squibb &amp; Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo, and Amgen Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Prolia
The findings are part of ICER's latest Unsupported Price Increases (UPI) report, which examines the top 10 drugs with significant net price increases in the past year.
ICER's Vice President of Research, Dr. Foluso Agboola, highlighted the impact of these price hikes, noting they exceed inflation rates and strain the healthcare system.
The ICER report highlighted that Gilead's Biktarvy saw its wholesale acquisition cost increase by 5.9%, with its hike costing U.S. payers $359 million in additional drug spending.
According to the ICER report, the Darzalex price before discounts increased by 7.6%, compared to 6.2% for Entresto, 7.5% for Cabometyx, and 6% for Xeljanz.
Those price increases added an additional $190 million, $108 million, $86 million, and $72 million to 2023 U.S. drug spending, respectively.
Methodology Behind ICER's Findings
<ul>
<li>ICER's evaluation followed a detailed protocol introduced in April 2024. The organization assessed drugs meeting criteria such as ranking among the top 250 by U.S. sales revenue and exceeding consumer price index growth plus 2% in their Wholesale Acquisition Cost.</li>
<li>The analysis focused on distinguishing price increases driven by value from those unrelated to new clinical evidence.</li>
<li>Manufacturers provided input, and ICER reviewed published studies for evidence of additional health benefits.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42468724/warner-bros-discovery-restructures-with-focus-on-streaming-and-tv-divisions-stock-shoots-up" target="_blank" rel="noreferrer noopener">Warner Bros. Discovery Stock Spikes As Board OKs Restructuring Plan</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Media

AMGN

EXEL

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report

Bristol Myers Squibb Increases Quarterly Dividend From $0.60 To $0.62/Share

B of A Securities analyst Tim Anderson reinstates Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Neutral and announces $63 price target.

Initiation

B of A Securities Reinstates Neutral on Bristol-Myers Squibb, Announces $63 Price Target

Multiple analyses underscore durable efficacy and well-established safety profile of Breyanzi (lisocabtagene maraleucel; liso-cel) in leukemia and several types of lymphoma.
 &nbsp;

Bristol Myers Squibb Reports Results From 18 Presentations; Data Demonstrate Efficacy, Durability And Safety Of Currently Available Therapies In Blood Cancers

AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, today announced that it has entered a Research Collaboration and Option Agreement with Bristol Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) to discover and develop novel miniprotein-based therapeutics utilizing AI Proteins' powerful discovery platform.
Under this collaboration, AI Proteins will leverage its proprietary AI-driven platform to design and optimize miniproteins against targets of interest to Bristol Myers Squibb. These de novo designed miniproteins, characterized by their small size and high affinity, have the potential to offer significant advantages over traditional antibody-based therapies, including improved tissue penetration and rapid clearance.

AI Proteins Enters A Research Collaboration And Option Agreement With Bristol Myers Squibb To Discover And Develop Novel Miniprotein-Based Therapeutics Utilizing AI Proteins' Powerful Discovery Platform.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Bristol-Myers Squibb Company &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 4.00%</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and raised the price target from $55 to $60 on Nov. 12. This analyst has an accuracy rate of 72%.</li>
<li>Leerink Partners analyst David Risinger upgraded the stock from Market Perform to Outperform and raised the price target from $55 to $73 on Nov. 12. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: Bristol-Myers Squibb filed a lawsuit last week against the U.S. Health Resources and Services Administration (HRSA) and the U.S. Department of Health and Human Services (HHS), alleging that HRSA&#8217;s rejection of its proposed rebate model for the 340B Drug Pricing Program violates federal law.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1">latest BMY news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043144/image-15.png" alt="" class="wp-image-674099" style="width:737px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043144/image-15.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043144/image-15-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043144/image-15-768x713.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</h3>
<ul>
<li>Dividend Yield: 3.61%</li>
<li>Leerink Partners analyst David Risinger upgraded the stock from Market Perform to Outperform with a price target of $206 on Nov. 22. This analyst has an accuracy rate of 74%.</li>
<li>Citigroup analyst Geoff Meacham maintained a Buy rating and cut the price target from $226 to $215 on Nov. 12. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Nov. 18, AbbVie secured European Commission approval for ELAHERE, first novel therapy for platinum-resistant ovarian cancer.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1"> latest ABBV new</a>s </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043214/image-16.png" alt="" class="wp-image-674101" style="width:652px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043214/image-16.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043214/image-16-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043214/image-16-768x708.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">Patterson Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>)</h3>
<ul>
<li>Dividend Yield: 4.75%</li>
<li>Baird analyst Jeff Johnson maintained a Neutral rating and cut the price target from $30 to $28 on Aug. 29. This analyst has an accuracy rate of 80%.</li>
<li>Morgan Stanley analyst Erin Wright maintained an Equal-Weight rating and lowered the price target from $35 to $28 on June 20. This analyst has an accuracy rate of 77%.</li>
<li>Recent News: Patterson Companies will hold its fiscal 2025 second-quarter conference call on Thursday, Dec. 5.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1">PDCO stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="922" height="846" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043251/image-17.png" alt="" class="wp-image-674102" style="width:652px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043251/image-17.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043251/image-17-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043251/image-17-768x705.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42267284/this-analyst-with-85-accuracy-rate-sees-more-than-8-upside-in-crowdstrike-here-are-5-stock-picks-for-november-from-wall-streets-most-accurate-analysts">This Analyst With 85% Accuracy Rate Sees More Than 8% Upside In CrowdStrike &#8211; Here Are 5 Stock Picks For November From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

PDCO

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields

On Monday, Purple Biotech Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) reported the final results from the randomized Phase 2 study of its lead oncology drug, CM24, a humanized monoclonal antibody that blocks CEACAM1, in patients with pancreatic <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42262840/purple-biotech-reports-positive-final-results-from-randomized-phase-2-study-of-cm24-in-second-line" rel="noreferrer noopener">ductal adenocarcinoma (PDAC)</a>.
Purple Biotech stock is trading higher with a strong session volume of 9.7 million, compared to an average volume of 48.73K as per data from <a href="https://www.benzinga.com/pro/feature/newsfeed" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
The Phase 2 study evaluated CM24 in combination with Bristol Myers Squibb &amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) immune checkpoint inhibitor nivolumab plus stand-of-care (SoC) chemotherapy in second-line metastatic PDAC patients versus SoC chemotherapy alone.
In the intent-to-treat cohort population, the median overall survival rate was 7.92 months in the CM24 combo treatment arm versus 5.55 months in the chemo arm.
The median progression-free survival was 3.9 months versus 2.0 months.
The overall response rate was 25% versus 7%, and the disease control rate was 63% compared to 47% in the CM24 combo arm vs. chemo alone group.
A consistent and continuous decrease of CA19-9, a clinically validated PDAC biomarker, was observed in the experimental arm, reaching a median percentage reduction from baseline of approximately 80% vs. an increase of 40% in the control arm.&nbsp;
A biomarker-enriched patient population analysis based on pretreatment ranges of serum CEACAM1 demonstrated significant improvement in the treatment arm over the control, with a 79% reduction in the risk of death and a median overall survival improvement of 5.1 months.
Over 90% reduction in risk of progression or death was observed, with a median progression-free survival improvement of 2.9 months and improvement in the treatment arm over the control, resulting in an overall response rate of 50% vs. 0%.
The CM24+nivolumab+Nal/IRI/5FU/LV regimen was well tolerated. The most frequent treatment-emergent Grade 3 or higher adverse events were diarrhea, fatigue, and neutropenia.
Accordingly, no meaningful differences in safety and tolerability were observed between the experimental arm and the SoC arm.
Price Action: PPBT stock is up 54.1% at $5.17 during the premarket session at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42265847/biden-targets-china-with-new-chip-restrictions-nvidia-slides" target="_blank" rel="noreferrer noopener">Biden Targets China With New Chip Restrictions, Nvidia Slides</a></li>
</ul>
Photo via Shutterstock.

PPBT

Why Is Purple Biotech Stock Trading Higher On Monday?

JPMorgan analyst Chris Schott added Bristol Myers (BMY) to the firm's Analyst Focus List as a value idea and keeps an Overweight rating on the shar...

Bristol Myers added to Analyst Focus List at JPMorgan

Impax Small Cap Fund Q3 2024 Commentary

Regeneron reports positive results for two anti-coagulant drugs

Bristol in license agreement with BioArctic for two Alzheimer's antibody programs

Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued

Bristol-Myers Squibb: Rich Dividends & Double-Digits Upside Potential - Bright 2026 Prospects

What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street's best analysts during...

Buy/Sell: Wall Street's top 10 stock calls this week

What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Dec. 16-20, 2024.

Wall Street's Top 10 Stock Calls This Week - Saturday, Dec. 21

Prothena Surges After Parkinson's Drug Misses Primary Endpoint

SA Asks: Which Big Pharmas are likely to announce big M&A deals?

AGEN

BIIB

BMYMP

COMM

CRSP

CSIQ

ESALF

GNRC

HCAT

HERC

INSP

LGND

LGNDZ

LGNXZ

LGNYZ

LGNZZ

MRNA

NBIX

PCRX

PRTA

SEDG

TGLS

TTGT

VCTR

Screenshot 2024-02-29 at 7.16.11 PM

ATNM

COEP

Here&#39;s How Coeptis Therapeutics Is Innovating Cell Therapy Approaches

Press Releases

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Bristol Myers Squibb's Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms

Bristol Myers Squibb to Participate in Citi's 2024 Global Healthcare Conference

AI Proteins Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400M

Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline

Bristol Myers Squibb Announces Dividend Increase

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

insitro Receives $25 Million in Milestone Payments from Bristol Myers Squibb for the Achievement of Discovery Milestones and the Selection of First Novel Genetic Target for ALS

BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program

Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025

Comments

Bristol-Myers Squibb

매도 수량

Bristol-Myers Squibb (NYSE:BMY) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌